Risk for infantile spasms after acute symptomatic neonatal seizures

Hannah C Glass1,2,3, Zachary M Grinspan4, Yi Li5

  • 1Department of Neurology and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Epilepsia
|November 14, 2020
PubMed

Insights

A new prediction rule accurately identifies neonates at high risk for infantile spasms (IS), a severe early childhood epilepsy. This tool uses EEG, MRI, and clinical data to stratify risk, enabling earlier diagnosis and treatment for better outcomes.

Area of Science:

  • Neonatal neurology
  • Pediatric epilepsy
  • Clinical prediction modeling

Background:

  • Infantile spasms (IS) is a severe form of epilepsy in early childhood.
  • Early treatment of IS is crucial for seizure remission and optimal developmental outcomes.
  • Predicting IS risk in neonates with acute symptomatic seizures is essential for timely intervention.

Purpose of the Study:

  • To develop and validate a prediction rule for identifying neonates with acute symptomatic seizures who are likely to develop IS.
  • To stratify the risk of IS based on readily available clinical, EEG, and MRI data.
  • To aid in clinical counseling and participant selection for clinical trials aimed at preventing post-neonatal epilepsy.

Main Methods:

  • Utilized data from the Neonatal Seizure Registry, a prospective, multicenter cohort study.
  • Included neonates with acute symptomatic seizures, clinical EEG, MRI, and age under 2 years.
  • Employed bivariate analysis and best subsets logistic regression to identify predictors of IS, followed by a consensus process for model selection.

Main Results:

  • Infantile spasms (IS) developed in 6% of the 204 infants studied.
  • Key predictors identified were: severely abnormal EEG or prolonged seizures on EEG, deep gray or brainstem injury on MRI, and abnormal tone on discharge exam.
  • Risk stratification showed 0% IS risk for infants with no factors, 4% with one or two factors, and 57% with all three factors.

Conclusions:

  • A risk prediction rule using common clinical data can effectively stratify IS risk in neonates with acute symptomatic seizures.
  • The rule identifies a high-risk group (all three factors) with over 50% developing IS, versus 0% in the low-risk group.
  • This prediction tool can guide clinical counseling, trial recruitment, and ultimately improve outcomes for infants with this devastating epilepsy.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
644
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
928
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
726
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
760
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
649